aprutumab
- Generic Name
- aprutumab
First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 35
- Registration Number
- NCT01881217
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath